DEKA Laser and New York’s Romeo & Juliette: A Global Partnership for Advanced Epilation on Fifth Avenue
4.12.2024 13:00:00 CET | Business Wire | Press release
DEKA Laser, global leader in medical laser technologies, proudly announces its new and prestigious partnership with Romeo & Juliette Hair Removal, the renowned center specialized in permanent hair removal located on world-famous Fifth Avenue in New York City. Thanks to this exclusive collaboration, Romeo & Juliette will become another global reference center for DEKA training on laser hair removal, with particular attention to the Again PRO Series line of equipment, and will host the innovative DEKA Epil Academy, an academy dedicated to the training and sharing of advanced hair removal treatment protocols.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241204652458/en/
Located on one of the most elegant and most renowned avenues in the world, Romeo & Juliette Hair Removal is considered true excellence in the aesthetic and medical realm, and is frequented by celebrities, top models and prominent sports personalities. This new international training center will become the reference point for physicians and specialists from all over the world who wish to train on the most innovative and effective laser hair removal protocols, in particular for the treatment of all phototypes.
“The collaboration with Romeo & Juliette represents a significant achievement for DEKA”, says Paolo Salvadeo, DEKA Laser’s CEO. “This partnership allows us to take our quality and innovation standards to one of the most iconic and prestigious locations in the world, making the training experience unique in its type. I am proud to be able to give life to this project, which will contribute to the growth and diffusion of the Again PRO technology and our advanced hair removal protocols.
Also Chris Karavolas, Director of the Romeo & Juliette Center, expresses his enthusiasm for this new phase: “We are thrilled to cooperate with DEKA, a subsidiary of the El.En. Group, an absolute reference company in the world of laser technology. This synergy will allow us to offer cutting-edge treatments to our clients, constantly optimizing the protocols for every skin type. For us working side by side with DEKA and El.En. Group represents a unique growth and development opportunity”.
Chris Karavolas, with over twenty years of experience in the hair removal field, will work closely with the DEKA team to perfect the treatment protocols for every skin type, contributing to positioning Romeo & Juliette and DEKA Laser as global leaders in the sector.
The DEKA Epil Academy will position itself as a center of excellence in the hair removal training, attracting professionals the world over toward the famous Fifth Avenue, a meeting place of innovation, beauty and technology.
https://dekalaser.com/products/again-pro/
https://www.romeojuliettelaserhairremoval.com/
Information on DEKA
DEKA is a subsidiary of the EL.EN. multinational Group which has been the leader in the laser work for 40 years.
This Italian company, headquartered in Florence, has its roots in a culture whose dominant characteristic is excellence of thought. Thanks to its priceless cultural heritage and its unique historical background, DEKA enshrines a promise of universal value in its vision: Transforming each scientific discovery into a solid benefit for physicians and patients and translate each technological innovation into ongoing improvement in its product and services range to ameliorate the quality of people’s lives.
View source version on businesswire.com: https://www.businesswire.com/news/home/20241204652458/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Corona Global Named Most Valuable Beer Brand in Kantar BrandZ Rankings for Third Consecutive Year14.5.2026 06:01:00 CEST | Press release
AB InBev Holds 8 of the Top 10 Most Valuable Beer Brands Globally Corona global has been recognized as the most valuable beer brand in the world for the third consecutive year in Kantar's BrandZ 2026 Most Valuable Global Brands report, released today. Eight out of the top ten most valuable global beer brands belong to AB InBev (Brussel:ABI) (BMV:ANB) (JSE:ANH) (NYSE:BUD), according to the report ranking the best brands in the world. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260513211378/en/ In 2025, Corona led AB InBev’s performance, increasing revenue by 8.3% outside of its home market with double-digit volume growth in 30 markets, while Corona Cero delivered strong double-digit volume growth. As the brand celebrated its 100th anniversary, Corona launched its global “Corona 100” platform, including a multi-year sponsorship of a renowned concert at Copacabana Beach in Rio de Janeiro. Strong momentum continued in Q1 2026
The Bolivarian Republic of Venezuela Announces the Initiation of a Comprehensive Public Debt Restructuring Process13.5.2026 22:08:00 CEST | Press release
The Bolivarian Republic of Venezuela announces today its decision to initiate a comprehensive restructuring of its external public debt obligations. CONTEXT & RATIONALE Over the past decade, Venezuela's economy has been severely impacted by external shocks – from the end of the commodity super-cycle to foreign sanctions and COVID-19 – resulting in a sharp economic contraction, a protracted default since 2017, and a ballooning of public sector liabilities. The country nonetheless possesses a strong economic potential, including unique hydrocarbon and mineral endowments. A recovery is underway, and Venezuela is committed to accelerating it through a comprehensive reform agenda in support of growth, fiscal sustainability, monetary stabilization, and enhanced governance. Restoring public debt sustainability is central to this agenda: the current debt overhang constrains external financing, limits public investment capacity, and prevents full re-engagement with the international financial s
Boomi Announces Intent to Acquire Lunar.dev to Deliver Governed Agent Connectivity Across the Enterprise13.5.2026 21:00:00 CEST | Press release
Proposed acquisition extends Boomi’s AI gateway capabilities, enabling enterprises to govern massive volumes of traffic for production-ready AI Boomi, the data activation company for AI, today announced it has signed a letter of intent to acquire Lunar.dev, an innovator in AI and MCP gateway. The proposed acquisition is expected to enrich the Boomi Enterprise Platform and Boomi Connect with advanced capabilities to govern and scale AI usage across enterprise systems. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260513850557/en/ Boomi Announces Intent to Acquire Lunar.dev to Deliver Governed Agent Connectivity Across the Enterprise As organizations move from AI experimentation to production, controlling how agents and AI applications interact with LLMs at scale has become critical. Lunar.dev addresses this need with an AI gateway that delivers granular, policy-driven control over AI interactions, with the visibility, securi
BeOne Medicines’ BEQALZI™ (sonrotoclax) Approved by U.S. FDA as First and Only BCL2 Inhibitor for R/R Mantle Cell Lymphoma13.5.2026 19:27:00 CEST | Press release
BEQALZI is a foundational BCL2 inhibitor designed for greater potency and selectivity, with potential to improve efficacy, tolerability, and convenience versus others in the classApproval of BEQALZI marks the first new BCL2 inhibitor approved in a decade in the U.S. and the only BCL2 inhibitor approved in MCL, aiming to set a new standard of innovation BeOne Medicines Ltd. (“BeOne”) (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval to BEQALZI™(bee-KAHL-zee; sonrotoclax), a foundational, next-generation BCL2 inhibitor, for the treatment of adult patients with relapsed or refractory (R/R) mantle cell lymphoma (MCL), after at least two lines of systemic therapy, including a Bruton’s tyrosine kinase (BTK) inhibitor. BEQALZI was designed to enhance BCL2 inhibition—with greater potency, selectivity, and a pharmacologic profile with potential to improve efficacy, tolerability, a
Boomi Unveils Innovations That Power the Agentic Enterprise13.5.2026 16:30:00 CEST | Press release
Orchestration capabilities simplify workflows, while advanced agent connectivity and an enhanced context layer activate data and scale AI Boomi, the data activation company for AI, today announced a major expansion of the Boomi Enterprise Platform at Boomi World 2026, introducing new capabilities across orchestrated agentic workflows, agentic engineering, governed agent connectivity, grounded agent context, and localized agent infrastructure. Together, these innovations are designed to power the agentic enterprise — where agents and humans work together to drive action and operationalize AI at scale. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260513996223/en/ Boomi Unveils Innovations That Power the Agentic Enterprise The enterprise has reached a defining moment as AI becomes the primary interface for work and MCP emerges as the new standard. While the shift toward a headless, agentic enterprise is inevitable, this visio
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom